EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

VEXAS: A review of current understandings and emerging treatment strategies

Robert Holden, Yogeshraj Jeelal, Andrew McLean-Tooke, Kylan Pathmanathan, David Nolan

Frontiers in Immunology · 28.07.2025 · 16

DOI: 10.3389/fimmu.2025.1644404 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 28.07.2025. Verfasst von Robert Holden und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology, Royal Perth Hospital, Perth, WA, Australia. Hauptthemen laut MEDLINE: Hereditary Autoinflammatory Diseases, Genetic Diseases, X-Linked. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a late-onset autoinflammatory disorder, typically affecting males, caused by somatic mutations in the X-linked gene UBA1 encoding the E1 ubiquitin-activating enzyme. These mutations result in defective ubiquitination and dysregulation of protein degradation, leading to Endoplasmic Reticulum stress and activation of innate immune pathways. This leads to significant inflammatory manifestations including fever, chondritis, neutrophilic dermatoses, and cytopenia’s and a range of inflammatory manifestations that define the clinical syndrome. Alongside these autoinflammatory manifestations, VEXAS exhibits features of clonal haematopoiesis, with clonal dominance of UBA1-mutant haematopoietic stem and progenitor cells with preferential myeloid differentiation and impaired generation of megakaryocytes, erythroid and lymphoid cells. The convergence of somatic mutation, inflammation, and bone marrow failure situates VEXAS at the interface of autoinflammation and hematologic neoplasia. Therapeutic approaches have focused on immunosuppression (e.g., corticosteroids, IL-6 inhibitors, JAK inhibitors), though these often yield only partial responses. Targeted therapies aimed at the mutant clone—including hypomethylating agents are under investigation. Allogeneic hematopoietic stem cell transplantation remains the only curative strategy. This review synthesises recent genetic, cellular, and clinical advances to consider VEXAS as an age-related proteosomopathy that unites clonal haematopoiesis with innate-immune dysregulation and provides appraisal of both established immunomodulators and emerging clone-directed therapies in addition to advocating harmonised response criteria, thereby offering a cohesive roadmap for future mechanistic studies and trial design in this rapidly evolving field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hereditary Autoinflammatory DiseasesGenetic Diseases, X-LinkedHumansMutationHematopoietic Stem Cell TransplantationAnimalsMyelodysplastic SyndromesSkin Diseases, Genetic

Stichwörter der Autor:innen

VEXASVEXAS syndromeautoinflamatory diseasesmyelodyslastic syndromesmyeloid cells

Autor:innen und Institutionen

  • Clinical Immunology, Royal Perth Hospital, Perth, WA, Australia.
  • Haematology, Royal Perth Hospital, Perth, WA, Australia.
  • Medical School, University of Western Australia, Perth, WA, Australia.
  • Clinical Immunology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
  • Rheumatology, Sir Charles Gairdner Hospital, Perth, WA, Australia.

Zitieren

APA

Holden, R., Jeelal, Y., McLean-Tooke, A., Pathmanathan, K., & Nolan, D. (2025). VEXAS: A review of current understandings and emerging treatment strategies. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1644404

Vancouver

Holden R, Jeelal Y, McLean-Tooke A, Pathmanathan K, Nolan D. VEXAS: A review of current understandings and emerging treatment strategies. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1644404

BibTeX
@article{Holden2025,
  author = {Holden, Robert and Jeelal, Yogeshraj and McLean-Tooke, Andrew and Pathmanathan, Kylan and Nolan, David},
  title = {VEXAS: A review of current understandings and emerging treatment strategies},
  journal = {Frontiers in Immunology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fimmu.2025.1644404}
}
Kostenlos starten →